European Commission warns UK over drug authorisation validity due to Brexit
pharmafile | May 4, 2017 | News story | Medical Communications, Sales and Marketing | EMA, European Commission, brexit
The European Commission has issued a warning to pharmaceutical firms in the UK over the validity of current and future drug authorisations in the wake of Brexit.
In a statement, the organisation reiterated that, under EU law, it is required for any authorisation holders to be established in one of the European Union member states or an EEA country. Given the Britain’s exit from the Union and its revocation of its status as a member state, drug companies that are purely UK-based could see their product approvals disrupted.
Such companies are urged to screen authorisations which are likely to be affected by the UK’s exit in March 2019.
In the release Notice to marketing authorisation holders of centrally authorised medicinal products for human and veterinary use, the Commission noted: “Marketing authorisation holders may be required to adapt processes and to consider changes to the terms of the marketing authorisation holders may be required to adapt processes and to consider changes to the terms of the marketing authorisation in order to ensure its continuous validity and exploitation, once the United Kingdom has left the Union.”
The statement continued: “In particular, the Commission and the European Medicines Agency expect marketing authorisation holders to prepare and proactively screen authorisations they hold for the need for any changes. The necessary transfer or variation requests will need to be submitted in due time considering the procedural timelines foreseen in the regulatory framework.”
Major industry associations, including the ABPI and the BioIndustry Association, have recently called for close co-operation with the next UK Government to strengthen life science prospects and to smooth the difficult transition period over the course of Brexit and beyond.
Matt Fellows
Related Content
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
